Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Adcetris® for the Treatment of Relapsed or Refractory Hodgkin’s Lymphoma

Adcetris® (brentuximab vedotin) was developed by Seattle Genetics along with Millenium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceutical.



Go Top